Medicine and Dentistry

1. Patient 100%
2. Maturity Onset Diabetes of the Young 85%
3. Diabetes 77%
4. Microalbuminuria 59%
5. Rosiglitazone 51%
6. Albuminuria 46%
7. Hypertension 46%
8. Therapeutic Procedure 45%
9. Diabetes Mellitus 41%
10. Patient with Type 2 Diabetes 36%
11. Glibenclamide 34%
12. Nephropathy 34%
13. Glycon 33%
14. Diabetic Nephropathy 32%
15. Cardiovascular Disease 28%
16. Cardiovascular System 27%
17. Urinary System 21%
18. Cardiovascular Risk 21%
19. Monotherapy 19%
20. Albumin 17%
21. Excretion 16%
22. Lifestyle Modification 16%
23. Obesity 16%
24. Clinical Trial 15%
25. Follow up 15%
26. Lipid 15%
27. Beta Cell 15%
28. C Reactive Protein 14%
29. Pulse Wave Velocity 14%
30. Glycemic Control 13%
31. Deterioration 13%
32. Cells 13%
33. Proteinuria 12%
34. Randomized Controlled Trial 12%
35. Water-Electrolyte Imbalance 12%
36. Glucose 11%
37. Drug 11%
38. In Vitro 11%
39. Transforming Growth Factor Beta1 11%
40. Male 10%
41. Metabolic Syndrome 10%
42. Creatinine 10%
43. Primary Prevention 10%
44. Cardiometabolic Risk 10%
45. Patient with Type 1 Diabetes 10%
46. Body Mass Index 10%
47. Kidney 9%
48. End Stage Renal Disease 9%
49. Impaired Glucose Tolerance 9%
50. Prevalence 9%